Literature DB >> 9561326

Progressive cerebral degeneration of childhood with liver disease (Alpers Huttenlocher disease) with cytochrome oxidase deficiency presenting with epilepsia partialis continua as the first clinical manifestation.

H Wörle1, B Köhler, W Schlote, P Winkler, C K Bastanier.   

Abstract

A previously healthy and normally developed 17-year-old young female presented with a sudden onset of focal motor seizure status that proved to be refractory to anticonvulsive treatment. Severe encephalopathy with visual impairment leading to blindness, mental deterioration, and predominantly left spastic tetraparesis developed progressively. Hepatic disease evolved 4 months after onset of the first symptoms and led to death in hepatic failure 1 month later. Diagnostic studies revealed an elevated protein and lactate in the cerebrospinal fluid, slow-wave and intermittently continuous spike-wave activity in the EEG, and a complex i.v. (cytochrome-C oxidase) deficiency in the muscle biopsy. MRI scans revealed signal abnormalities in the occipital lobe, thalamus, and basal ganglia only after 3 months. Histopathological findings in liver biopsy and in postmortem brain examination displaying widespread predominantly right cortical spongiosis, neuronal loss and astrocytosis were consistent with the clinically suspected diagnosis of progressive neuronal degeneration of childhood with liver disease (PNDC) or Alpers Huttenlocher disease. This rare disorder of unknown origin is usually seen in infants and young children and is rarely reported in adolescence.

Entities:  

Mesh:

Year:  1998        PMID: 9561326

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  4 in total

Review 1.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

2.  Rod bipolar cell dysfunction in POLG retinopathy.

Authors:  Kit Green Sanderson; Eoghan Millar; Anupreet Tumber; Regan Klatt; Neal Sondheimer; Ajoy Vincent
Journal:  Doc Ophthalmol       Date:  2020-06-21       Impact factor: 2.379

3.  Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions.

Authors:  Emilio L Streck; Gabriela K Ferreira; Giselli Scaini; Gislaine T Rezin; Cinara L Gonçalves; Isabela C Jeremias; Alexandra I Zugno; Gustavo C Ferreira; Jeverson Moreira; Celine M Fochesato; Pedro R T Romão
Journal:  Neurochem Res       Date:  2011-03-02       Impact factor: 4.414

4.  Lethal neonatal mitochondrial phenotype caused by a novel polymerase subunit gamma mutation: A case report.

Authors:  Mohamed F AlJabri; Naglaa M Kamal; Abdulrahman Halabi; Haifa Korbi; Mashhour M A Alsayyali; Yahea A Alzahrani
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.